Organigram Global Inc. is moving quickly to bring the Organigram Global Sanity Group into one global operating structure. The move will align leadership, operations and market development across key international markets. The combined platform will link Canada to Germany and other priority markets. These markets are Switzerland, Poland, Czechia, United Kingdom and Australia. The integration is a next step in Organigram’s global growth strategy. It also aligns Sanity Group GmbH more closely to Organigram’s overall operating model.
As part of the transition, Organigram appointed Finn Age Hänsel as President, Rest of World & Chief Strategy Officer. The Company also appointed Adrian Frenzel as Global Chief Operating Officer. Meanwhile, Tim Emberg will continue serving as President, Canada. His role will support the Company’s established Canadian commercial operations.
The integrated network will combine Canadian production with European commercial capabilities. It will also strengthen regulatory expertise and international distribution operations. Sanity has already become an important contributor to Organigram’s financial performance. The business contributed approximately CAD$40 million to consolidated net revenue. That contribution represented more than 35% of Organigram’s net revenue during its most recent quarter. Sanity also remained accretive to Adjusted EBITDA. Furthermore, Sanity continues to demonstrate strong revenue momentum. Its quarterly revenue increased 34% since December 31, 2025. The business reported quarterly revenue of €25.5 million. This performance further supports Organigram’s decision to deepen the integration.
Building a Unified International Cannabis Platform
The Sanity Group is well positioned in the German medical cannabis market. Organigram has a well established commercial platform to a large European market. Germany is one of Europe’s biggest and fastest-growing medical cannabis markets. The German market was estimated at over €2 billion in 2025. During that time the market served around 800,000 patients. The market is expected to grow further over the coming years. Germany’s medical cannabis market is expected to reach more than €4 billion in value by 2028. There is a lot of scope for further international expansion in the market.
Sanity also brings valuable European regulatory knowledge to the combined organization. The company has established operations in Switzerland and continues international expansion. Its strategic growth plans include Poland, the United Kingdom and Czechia. These markets provide additional opportunities for Organigram’s international development.
Meanwhile, Organigram has established capabilities across cultivation and manufacturing. The Company also focuses on product innovation, brands and international supply. Organigram currently supplies bulk cannabis shipments to Germany, Australia and the United Kingdom. The Company also recently introduced 10 product SKUs in Australia’s medical cannabis market. Bringing these operations together can improve coordination across the international supply network. It can also help Organigram strengthen product and brand commercialization.
The unified model will connect Canadian production capabilities with Sanity’s European infrastructure. That structure is expected to support supply planning and international market development. Additionally, Organigram can pursue new opportunities across Germany and other international markets. The approach supports the Company’s broader global cannabis growth strategy.
Leadership Appointments Strengthen Global Operations
Finn Age Hänsel now serves as President, Rest of World & Chief Strategy Officer. He will oversee global corporate strategy and international market development. He will also lead strategic partnership initiatives across the Company’s international operations. In addition, Hänsel will support the continued integration of Canadian and European capabilities. His responsibilities will include evaluating opportunities in additional international markets. He will also assess opportunities involving Organigram brands, products and intellectual property. Hänsel brings more than 15 years of entrepreneurial and executive experience. His career includes leadership roles across consumer and healthcare businesses. He began his professional career as a consultant at Boston Consulting Group. Later, he co-founded Sanity Group in 2018.
Under his leadership, Sanity developed into one of Germany’s leading medical cannabis companies. Its portfolio includes medical cannabis, wellness offerings and adult-use cannabis pilot projects. Previously, Hänsel co-founded The Iconic, a major Australian online fashion retailer. He also led the turnaround of relocation platform Movinga as CEO. Adrian Frenzel has also taken on a new leadership role at Organigram. He now serves as Global Chief Operating Officer.
Frenzel will oversee operational excellence across Organigram’s global business. His responsibilities will include operations and supply chain management. Initially, he will focus on improving operational performance across the consolidated organization. He will also drive greater alignment between global teams.
Furthermore, Frenzel will establish scalable operating practices across the business. He will also support efforts to expand gross margins. Frenzel brings more than a decade of executive and operational leadership experience. He previously served as Managing Director and COO of Sanity Group. Earlier in his career, he worked in operations consulting at McKinsey & Company. He also served as COO of Gorillas Technologies. In addition, Frenzel previously held the position of Co-CEO at HelloFresh USA.
Integrated Structure Supports Long-Term Growth
The leadership changes form an important part of Organigram’s broader integration strategy. The Company expects unified operations to improve execution across its markets.
“Organigram has built a strong foundation and, through Sanity, established a meaningful platform in Europe. With a unified leadership team and operating structure, we are now positioned to bring these capabilities together, pursue growth with greater focus and move more quickly on opportunities across our markets,” added James Yamanaka.
Yamanaka also highlighted the importance of the Company’s combined capabilities. Organigram believes the new structure can support more coordinated international expansion. The integrated approach can also help teams allocate resources more efficiently. At the same time, it can support growth and margin expansion. Organigram intends to build on the momentum created since completing the Sanity acquisition. The Company also expects greater collaboration between its Canadian and European operations.
Amended Sanity Group Earnout Agreement
Organigram has also amended the share purchase agreement governing the Sanity acquisition. The original agreement required Sanity to operate independently during a 12-month earnout period. The amendment changes the performance-based earnout structure. Instead, the parties agreed to establish a fixed earnout value. However, the revised arrangement retains the original payment structure. The earnout will remain payable after the conclusion of the applicable earnout period.
Under the amended agreement, the parties fixed the Sanity Group earnout at 85%. This represents 85% of the maximum earnout value under the original acquisition agreement. The revised structure provides greater certainty around the remaining acquisition consideration. It also creates clearer expectations for Organigram and the other parties involved. The earnout will include €20 million in cash.
The remaining consideration will be approximately €76 million. That amount remains subject to deductions and Organigram’s pre-acquisition interests. The remaining consideration will be payable through Organigram common shares.
The number of shares will depend on Organigram’s 20-day volume-weighted average trading price. The relevant VWAP will be calculated on the TSX. The calculation will use the trading price from three days before the payment date. The agreement also establishes a floor price of C$3.00 per share.
A cap price of C$4.00 per share will also apply. These conditions determine the number of common shares issued under the amended arrangement. The earnout consideration becomes payable on April 1, 2027. The cash payment and share issuance will occur no later than May 1, 2027. The payment remains subject to the terms and conditions of the amended agreement.
Organigram Targets Greater Operational Alignment
The Company believes Sanity’s performance supports its confidence in the business. Sanity has maintained strong momentum since Organigram completed the acquisition.
“Sanity has performed strongly since the acquisition, and its continued momentum reinforces our confidence in the growth trajectory of the business,” said Peter Amirault, Chairman of the Board of Organigram.
Amirault also pointed to expected revenue and Adjusted EBITDA growth. He noted the potential benefits from completing the broader integration. Organigram believes fixing the earnout at 85% provides a fair outcome. The structure also provides greater clarity for the Company moving forward. Meanwhile, Finn will focus on accelerating international growth. Adrian will lead operational excellence and margin expansion across the global platform.
Tim Emberg will continue leading Organigram’s commercial operation in Canada. This structure gives each executive a defined responsibility within the combined organization. The Company expects this approach to strengthen strategic alignment across its markets. It also aims to support profitable growth in Canada and internationally.
Regulatory Considerations Under MI 61-101
The amended earnout agreement qualifies as a related party transaction. This classification falls under Multilateral Instrument 61-101. MI 61-101 covers the protection of minority security holders in special transactions. However, the amended agreement qualifies for exemptions under the applicable provisions.
The agreement is exempt from formal valuation requirements under section 5.5(a). It also qualifies for an exemption from minority shareholder approval requirements. That exemption applies under section 5.7(1)(a) of MI 61-101. The applicable conditions relate to the fair market value and consideration involved. Neither the fair market value of the subject matter exceeds the applicable threshold. The same applies to the consideration for the amended earnout.
The connected transactions also remain below the relevant threshold. For MI 61-101 purposes, that threshold represents 25% of the Company’s market capitalization. As a result, Organigram can proceed with the amended earnout structure under the applicable exemptions.
Overall, the Organigram Global Sanity Group integration strengthens the Company’s international operating model. It combines Canadian production capabilities with Sanity’s European commercial infrastructure.
Global operations now have clear accountability with the leadership appointments. At the same time, the revised earnout provides more financial certainty. Organigram now has a much broader platform in Canada and across several international cannabis markets. The Company expects that the consolidated structure will lead to improved operational efficiency and international expansion. The strategy also enables Organigram to pursue opportunities in both established and emerging markets. “Consequently, the Company is now entering its next phase of global growth with an integrated operational approach.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
